王宏伟的加入,正好补上了康宁杰瑞最核心的短板——产业化能力。出品|读商时代责编|李晓燕3月11日,曾经掌握恒瑞医药核心生物药生产体系的王宏伟,跨出熟悉的舒适圈,加盟康宁杰瑞出任首席技术官(CTO)。表面上,这只是一次高管跳槽,但背后映射出康宁杰瑞正在经历的关键转型:当核心双抗和ADC管线逐步接近上市,公司发展的焦点不再只是创新研发,而是如何把实验室的突破变成可持续供应的商业化产品。王宏伟的加入,...
Source Link王宏伟的加入,正好补上了康宁杰瑞最核心的短板——产业化能力。出品|读商时代责编|李晓燕3月11日,曾经掌握恒瑞医药核心生物药生产体系的王宏伟,跨出熟悉的舒适圈,加盟康宁杰瑞出任首席技术官(CTO)。表面上,这只是一次高管跳槽,但背后映射出康宁杰瑞正在经历的关键转型:当核心双抗和ADC管线逐步接近上市,公司发展的焦点不再只是创新研发,而是如何把实验室的突破变成可持续供应的商业化产品。王宏伟的加入,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.